+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 227 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating two different pacing methods for patients with slow heart rates, called bradycardia. This study compares the common right ventricular pacing approach with a newer physiological pacing method that includes His bundle and left bundle area pacing. The trial aims to better understand how these pacing techniques affect patient outcomes, including mortality and heart failure morbidity, in a large group of 2600 patients. Participants will receive a pacemaker implant and be randomly assigned to either right ventricular pacing or physiological pacing. The physiological pacing may involve His bundle pacing or left bundle pacing, but if these are not successful, biventricular pacing will be used. A subgroup of 500 participants will take part in an optional echocardiographic sub-study to assess heart function changes over a 24-month period. Throughout the study, patients will be assessed at baseline and every six months after randomization, with follow-up lasting up to 78 months. Researchers will monitor outcomes such as mortality, heart failure events, device-related safety issues, patient quality of life, symptoms, and pacemaker-derived data like arrhythmias and activity levels. The echocardiographic sub-study will measure specific heart function changes to understand pacing-induced cardiomyopathy. Participants involvement includes implantation, regular follow-up visits, questionnaires, and optional imaging assessments.

Age: 18Years +All GendersPhase Not Applicable
45 locations
O

Actively Recruiting

Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.

Age: 18Years +All GendersPhase 1Phase 2
23 locations
E

Actively Recruiting

Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.

Age: 18Years +All GendersPhase 3
106 locations
E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety, tolerability, and how LY3962681 behaves in the body pharmacokineticspharmacodynamics in healthy volunteers and patients with Parkinsons disease. The trial has two parts a Single Ascending Dose SAD study with healthy volunteers and a Multiple Ascending Dose MAD study with Parkinsons patients. This study is a Phase 1, randomized, double-blind, placebo-controlled trial sponsored by Prevail Therapeutics. In the SAD part, healthy volunteers receive a single intrathecal into spinal fluid dose of LY3962681 or placebo artificial cerebrospinal fluid. In the MAD part, Parkinsons patients receive two intrathecal doses of LY3962681 or placebo spaced 12 to 24 weeks apart. The SAD treatment period lasts one day, while the MAD treatment includes two dosing days spaced several months apart. Participants will undergo safety and tolerability assessments over follow-up periods up to 52 weeks after dosing. Evaluations include monitoring for serious and treatment-emergent adverse events, measuring drug levels in the body, and assessing changes in cerebrospinal fluid biomarkers related to Parkinsons disease. The total study duration may extend for up to 76 weeks, including treatment and follow-up phases.

Age: 30Years - 80YearsAll GendersPhase 1
16 locations
E

Actively Recruiting

Researchers are evaluating the safety of LY3954068 in adults aged 50 to 85 with early symptomatic Alzheimers Disease. This Phase 1 study also investigates how much LY3954068 enters the bloodstream and examines its effects on Alzheimers disease markers. The study is divided into two parts to assess different dosing strategies. In Part A, each participant receives a single dose of LY3954068 or placebo injected into the spinal fluid. In Part B, participants may receive up to four doses of LY3954068 or placebo administered the same way. There is also an optional bridging period where participants might receive LY3954068 in a separate study. The study lasts about 45 weeks for Part A and up to 100 weeks for Part B, including screening. Participants will undergo various assessments such as spinal fluid sampling, blood tests, and PET scans using Flortaucipir F18 to observe tau protein changes. Safety is monitored by tracking adverse events related to the study drug. Cognitive tests like the Mini Mental State Examination and Clinical Dementia Rating are used to evaluate memory and dementia severity. Regular visits occur throughout the study to collect data, monitor health, and assess treatment effects.

Age: 50Years - 85YearsAll GendersPhase 1
10 locations
L

Actively Recruiting

Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.

Age: 18Years +All GendersPhase 3
118 locations
G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
A

Actively Recruiting

Relapsed neuroblastoma is a common and serious childhood cancer that is difficult to treat, especially in high-risk cases where the disease returns after initial treatment or does not respond to standard therapies. This trial aims to improve survival for children aged 1 year and older with relapsed neuroblastoma by testing new combinations of treatments. It is an international, open-label, randomized phase III study designed to develop and evaluate these new therapies while also studying the biology of the disease using biomarker samples. Participants will be randomly assigned to one of two main treatment groups or enrolled in smaller dose confirmation groups testing new drug combinations. The current main treatments include combinations of dinutuximab beta, irinotecan, temozolomide, and bevacizumab given in 12 cycles every three weeks. Additional experimental groups may receive different combinations of these drugs. The trial includes a translational sub-study collecting tumor, blood, and bone marrow samples to better understand neuroblastoma and improve targeted therapies. During the study, patients will receive their assigned treatments over multiple cycles and be closely monitored for safety, treatment response, and quality of life. Researchers will perform various assessments including imaging scans, laboratory tests, and questionnaires to measure progression-free survival, side effects, and overall clinical benefit. Follow-up will continue up to five years after treatment to assess long-term outcomes and collect further data on patient health and disease progression.

Age: 1Year +All GendersPhase 1Phase 2
23 locations

1-10 of 227

1